Jefferies Downgrades Opthea (OPT.US) Rating to Underperform with Target Price of $1.00

Summary

Jefferies Investment Bank downgraded Opthea’s rating from ‘buy’ to ‘underperform’, setting a target price of $1.00. Opthea Ltd specializes in developing biological therapies for eye diseases and is currently working on a new biological therapy, OPT-302, related to the vascular endothelial growth factor and its associated targets. The company operates in both Australia and the United States.Stock Star

Impact Analysis

At the company level, Jefferies’ downgrade reflects recent challenges faced by Opthea, including the failure of its OPT-302 study to meet primary endpoints in age-related macular degeneration patients and concerns over its ongoing viability.Stock Star+ 2 This has likely influenced Jefferies’ decision by highlighting operational and financial risks. The downgrade may lead to decreased investor confidence and selling pressure on Opthea’s stock, given the lowered price target and negative outlook. Investors should be cautious, as Opthea’s future prospects depend heavily on its pipeline’s success and resolving viability issues.Stock Star